BC Extra | Aug 28, 2019
Clinical News

Aug. 28 Clinical Quick Takes: InDex's cobitolimod hits Phase IIb endpoint in UC; plus AstraZeneca and Mitsubishi

InDex's UC therapy heading for Phase III  InDex Pharmaceuticals Holding AB (SSE:INDEX) is planning Phase III testing of cobitolimod after the DNA-based immunomodulatory sequence (DIMS) therapy met the primary endpoint in the Phase IIb CONDUCT...
BC Extra | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

Increased momentum in the kidney disease space, sparked in part by an evolution in FDA's thinking about approvable endpoints, encouraged a VC syndicate to back newly launched Chinook with $65 million in series A funding....
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 10, 2019
Company News

With industry's growing kidney momentum, Everest begins building kidney portfolio

Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas. The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It...
BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead...
BC Week In Review | Nov 30, 2018
Clinical News

Vectura discontinues asthma therapy after Phase III miss

Vectura Group plc (LSE:VEC) said it will discontinue development of VR475 after both doses of the compound missed the primary endpoint in a Phase III trial to treat severe uncontrolled asthma. Both twice-daily 0.5 and...
BC Week In Review | Nov 9, 2018
Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
BC Extra | Nov 8, 2018
Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
BC Week In Review | Jun 22, 2018
Financial News

Calliditas raises over $70M in Swedish IPO

Renal disease company Calliditas Therapeutics AB (SSE:CALTX) raised SEK650 million ($73.4 million) on June 15 through the sale of 14 million shares at SEK45 in an IPO on NASDAQ Stockholm. The company expects to begin...
Items per page:
1 - 10 of 320